Metabolic Pathways: A Research Literature Overview

NOVA Q Research · Research Library

Metabolic Pathways: A Research Literature Overview

What the published research examines across incretin agonists, an amylin analog, a mitochondrial peptide, an enzyme cofactor, a glycoprotein hormone, and an NNMT inhibitor — from large phase-3 trials to preclinical-only compounds.

Neutral literature aggregation · Compiled by NOVA Q Research · Updated 2026-07-24 · 15 cited sources
In brief
  • Tirzepatide is an approved dual GIP/GLP-1 agonist with large phase-3 programs (SURPASS, SURMOUNT).
  • Retatrutide is an investigational triple agonist with phase-2 data; cagrilintide is an investigational amylin analog studied alone and with semaglutide.
  • MOTS-c and 5-amino-1MQ are studied predominantly in preclinical models; 5-amino-1MQ has no published human trials.
  • L-carnitine has human exercise-physiology and meta-analytic literature; HCG’s interventional record is largely decades old with acknowledged methodological limits.

Metabolic-pathway research spans several distinct molecular targets, and this category illustrates the breadth: incretin-based agonists at the GLP-1/GIP/glucagon receptors (tirzepatide, retatrutide), an amylin analog (cagrilintide), a mitochondrial-derived peptide (MOTS-c), an enzyme cofactor (L-carnitine), a glycoprotein hormone historically studied in weight protocols (HCG), and an NNMT inhibitor (5-amino-1MQ). Some are approved or investigational pharmaceuticals with registered trials; others are studied only in cells and animals.

Tirzepatide

Class / mechanism. A synthetic dual GIP and GLP-1 receptor agonist; an approved pharmaceutical (type 2 diabetes and chronic weight management) studied extensively in registered trials.

Tirzepatide has been evaluated in the large SURPASS (type 2 diabetes) and SURMOUNT (obesity) randomized programs, measuring endpoints such as HbA1c, body weight, and safety against placebo and active comparators. Trial designs are typically multicenter, double-blind, and phase 2–3.

Selected literature

  1. Frías JP, et al. 2021. “Tirzepatide versus semaglutide once weekly in type 2 diabetes” (SURPASS-2). N Engl J Med 385:503–515. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519Head-to-head RCT on HbA1c and body-weight endpoints.
  2. Jastreboff AM, et al. 2022. “Tirzepatide once weekly for the treatment of obesity” (SURMOUNT-1). N Engl J Med 387:205–216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038Phase-3 RCT on percent body-weight change vs placebo in obesity without diabetes.
Where the evidence is limited. Much pivotal data is industry-sponsored with defined inclusion criteria and finite follow-up; very-long-term outcomes and broad generalizability remain open questions.

Retatrutide

Class / mechanism. An investigational triple agonist at the GIP, GLP-1, and glucagon receptors. Not an approved drug; studied in phase 2–3 trials.

Retatrutide has been assessed in randomized, placebo- and active-controlled phase-2 trials in obesity and type 2 diabetes, reporting dose-dependent change in body weight, HbA1c, and adverse-event profiles. A phase-2a study also investigated liver-fat content in metabolic dysfunction-associated steatotic liver disease.

Selected literature

  1. Jastreboff AM, et al. 2023. “Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial.” N Engl J Med 389:514–526. https://www.nejm.org/doi/full/10.1056/NEJMoa230197248-week phase-2 dose-ranging RCT on percent body-weight change.
  2. Rosenstock J, et al. 2023. “Retatrutide for people with type 2 diabetes: a phase 2 trial.” Lancet 402:529–544. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01053-X/abstractPhase-2 trial on glycemic and body-weight endpoints.
  3. Sanyal AJ, et al. 2024. “Retatrutide for MASLD: a randomized phase 2a trial.” Nat Med. https://www.nature.com/articles/s41591-024-03018-2Phase-2a substudy using imaging to quantify liver-fat change.
Where the evidence is limited. As an investigational agent, the base is largely phase-2 with short durations; larger, longer phase-3 trials and independent replication are ongoing.

MOTS-c

Class / mechanism. A mitochondrial-derived peptide encoded within the 12S rRNA region of the mitochondrial genome, studied as a putative regulator of cellular metabolism and AMPK-related signaling.

Investigations examine MOTS-c in skeletal-muscle and adipose metabolism, insulin sensitivity, and exercise physiology across cell cultures, mice, and human athlete cohorts. Endpoints include glucose handling, metabolic-gene expression, animal physical performance, and circulating peptide levels after exercise. The mechanistic base is predominantly preclinical.

Selected literature

  1. Lee C, et al. 2015. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metab 21(3):443–454. PMID 25738459. https://pubmed.ncbi.nlm.nih.gov/25738459/Foundational study of MOTS-c metabolic effects in mouse models.
  2. Reynolds JC, et al. 2021. “MOTS-c is an exercise-induced mitochondrial-encoded regulator of physical decline.” Nat Commun 12:470. https://www.nature.com/articles/s41467-020-20790-0Exercise-induced expression and performance/muscle endpoints in mice and humans.
Where the evidence is limited. Much mechanistic evidence is preclinical; human data are largely observational or small-cohort, and standardized assays and controlled interventional trials remain limited.

L-carnitine

Class / mechanism. A quaternary-amine cofactor central to mitochondrial transport of long-chain fatty acids for beta-oxidation; studied as a dietary supplement and in carnitine-deficiency contexts.

L-carnitine has been investigated in human exercise-physiology studies (muscle carnitine content, fuel selection) and in randomized trials and meta-analyses examining body-weight and body-composition endpoints, from controlled crossover metabolic studies to pooled RCT meta-analyses.

Selected literature

  1. Wall BT, et al. 2011. “Chronic oral L-carnitine and carbohydrate increases muscle carnitine content and alters fuel metabolism during exercise in humans.” J Physiol 589:963–973. PMID 21224234. https://pubmed.ncbi.nlm.nih.gov/21224234/Controlled human study of muscle carnitine and exercise fuel use.
  2. Pooyandjoo M, et al. 2016. “The effect of L-carnitine on weight loss in adults: a systematic review and meta-analysis of RCTs.” Obes Rev 17(10):970–976. PMID 27335245. https://pubmed.ncbi.nlm.nih.gov/27335245/Meta-analysis pooling RCTs on body-weight endpoints.
Where the evidence is limited. Meta-analyses report heterogeneity across dose, duration, and population, and oral bioavailability is a recognized methodological constraint; effect estimates vary between trials.

HCG (human chorionic gonadotropin)

Class / mechanism. A placental glycoprotein hormone acting at the LH/hCG receptor; historically studied in calorie-restricted weight protocols and reproductive endocrinology, and examined in vitro on adipose tissue.

The published record includes placebo-controlled trials and criteria-based meta-analyses evaluating HCG within very-low-calorie protocols, with endpoints such as weight change, hunger, and well-being, plus in-vitro adipocyte work. Several reviews specifically appraised the methodological quality of earlier trials.

Selected literature

  1. Lijesen GK, et al. 1995. “The effect of HCG in the treatment of obesity (Simeons therapy): a criteria-based meta-analysis.” Br J Clin Pharmacol 40(3):237–243. https://pmc.ncbi.nlm.nih.gov/articles/PMC1365103/Criteria-based meta-analysis appraising controlled HCG trials.
  2. Asher WL, Harper HW. 1973. “Effect of HCG on weight loss, hunger, and feeling of well-being.” Am J Clin Nutr 26:211–218. PMID 4574032. https://pubmed.ncbi.nlm.nih.gov/4574032/Controlled trial measuring weight, hunger, and well-being.
Where the evidence is limited. The interventional literature is largely decades old, and meta-analytic appraisals highlight methodological limitations in the original trials; contemporary high-quality data are sparse.

Cagrilintide

Class / mechanism. An investigational long-acting amylin analog acting at amylin/calcitonin receptors, studied alone and in fixed combination with semaglutide (CagriSema). Not an approved standalone drug.

Cagrilintide has been evaluated in randomized phase-1b and phase-2 trials in overweight/obesity and type 2 diabetes, with endpoints including body-weight change, glycemic measures, pharmacokinetics/pharmacodynamics, and tolerability. Trials are multicenter, double-blind, and placebo- and/or active-controlled.

Selected literature

  1. Lau DCW, et al. 2021. “Once-weekly cagrilintide for weight management: a phase 2 dose-finding trial.” Lancet 398:2160–2172. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01751-7/abstractDose-finding phase-2 RCT on percent body-weight change.
  2. Enebo LB, et al. 2021. “Cagrilintide with semaglutide 2.4 mg for weight management: a phase 1b trial.” Lancet 397:1736–1748. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00845-X/abstractPhase-1b PK/PD, safety, and exploratory weight endpoints of the combination.
Where the evidence is limited. Evidence is concentrated in early-phase and combination-therapy trials with limited duration; larger phase-3 outcome data for cagrilintide as a distinct agent are still emerging.

5-amino-1MQ

Class / mechanism. A small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme implicated in NAD+/methylation metabolism in adipose tissue. Research is preclinical; there are no published human trials of this compound.

Foundational NNMT research used gene-knockdown in mice to examine adipose metabolism and diet-induced obesity, and subsequent work developed and tested membrane-permeable small-molecule NNMT inhibitors (including 5-amino-1-methylquinolinium) in cell and mouse models. Endpoints include body weight, adipocyte metabolism, cellular NAD+/SAM levels, and enzyme-inhibition potency.

Selected literature

  1. Kraus D, et al. 2014. “Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity.” Nature 508:258–262. PMID 24717514. https://pubmed.ncbi.nlm.nih.gov/24717514/Foundational NNMT-knockdown study of diet-induced obesity endpoints in mice.
  2. Neelakantan H, et al. 2018. “Selective membrane-permeable NNMT inhibitors reverse high-fat-diet-induced obesity in mice.” Biochem Pharmacol 147:141–152. PMID 29155147. https://pubmed.ncbi.nlm.nih.gov/29155147/Develops/tests NNMT inhibitors on metabolic endpoints in a high-fat-diet mouse model.
Where the evidence is limited. All available data are preclinical (in-vitro and rodent); there are no published human clinical trials, and human pharmacokinetics, safety, and efficacy for 5-amino-1MQ are uncharacterized.

How to read this report

This report aggregates published scientific literature for the compounds NOVA Q Research supplies in the Metabolic category. It describes what studies investigated, the models used, and the maturity of the evidence. It does not evaluate, recommend, or imply any use in humans or animals, and it is not medical, veterinary, or research-protocol advice. Where the record is preclinical or geographically concentrated, we say so. Every source is cited so it can be checked independently.

Browse the Metabolic catalog →
For research use only. Not for human or veterinary use. NOVA Q Research supplies research-grade materials for laboratory research use only. Nothing in this document is intended to diagnose, treat, cure, or prevent any disease, or to guide human or veterinary use. Statements have not been evaluated by the FDA. Citations are provided for reference and do not imply endorsement.